Spots Global Cancer Trial Database for Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma
Official Title: Phase 1 Study of the Safety and Tolerability of ATR-101 in Adrenocortical Carcinoma
Study ID: NCT01898715
Interventions
Study Description
Brief Summary: This first-in-human study is designed to establish the safety and tolerability of ATR-101 in patients with advanced adrenocortical carcinoma whose tumor has progressed on standard therapy. Information will also be collected to determine how long ATR-101 stays in the blood, and if any effect on tumor progression is seen. Biomarkers (blood and urine tests) will determine if any effects on production of steroid hormones (cortisol, aldosterone, estrogen and testosterone) are seen.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Moffitt Cancer Center, Tampa, Florida, United States
National Institutes of Health/National Cancer Institute, Bethesda, Maryland, United States
University of Michigan Cancer Center, Ann Arbor, Michigan, United States
MDAnderson Cancer Center, Houston, Texas, United States
Comprehensive Cancer Center Mainfranken, University Hospital of Würzburg, Würzburg, , Germany
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
